Protocol Ledger

NCT06982521 · Phase III · RECRUITING

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Interventional Phase III clinical trial protocol NCT06982521 sponsored by Relay Therapeutics in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-08-26 Enrollment: 540 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06982521
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)540 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06982521
Protocol FieldVerified Registry Value
NCT IdentifierNCT06982521
Consolidated Lead SponsorRelay Therapeutics
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment540 participants (ESTIMATED)
Registered Start Date2025-08-26
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06982521
Hospital Research SiteLocationSite Profile
Banner MD Anderson Cancer CenterGilbert, AZOpen Hospital Dossier ->
Beverly Hills Cancer CenterBeverly Hills, CAOpen Hospital Dossier ->
City of Hope National Medical CenterDuarte, CAOpen Hospital Dossier ->
Cedars-Sinai Medical CenterLos Angeles, CAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI